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AbstrACt
Objectives This study aimed to evaluate the effectiveness 
of multiple risk factor control (MRFC) at reducing mortality 
and cardiovascular events in diabetes and chronic kidney 
disease (CKD) in clinical practice.
Design Population-based cohort study.
setting Primary care database in the UK, linked with 
inpatient and mortality data.
Participants Participants aged 40–79 years with type 
2 diabetes and valid serum creatinine measurements, 
including 11 431 participants with CKD (estimated 
glomerular filtration rate: eGFR 15–59 mL/min/1.73 m2) 
and 36 429 participants with non-CKD (eGFR ≥60 mL/
min/1.73 m2).
Exposures MRFC consisted of four components: 
Haemoglobin A1c (HbA1c) <53 mmol/mol (<7.0%), blood 
pressure <140/90 mm Hg, total cholesterol <5 mmol/L and 
no smoking. The main exposure variable was the number 
of risk factors controlled at baseline.
Outcome measures All-cause and cardiovascular mortality 
in the overall participants. Cardiovascular events, including 
coronary heart disease and stroke, in participants limited to 
those without a history of cardiovascular diseases at baseline.
results In participants with CKD, 37% or 13% met three or 
four MRFC criteria, respectively. Increasing numbers of risk 
factors controlled were associated with lower relative hazards 
for all outcomes studied compared with those meeting no or 
one criterion. For participants with CKD meeting four criteria, 
the adjusted HR for all-cause mortality was 0.60 (95% CI 0.53 
to 0.69) and the adjusted subdistribution HR for cardiovascular 
mortality was 0.60 (95% CI 0.50 to 0.70), considering a 
competing risk of non-cardiovascular death. Participants 
meeting four criteria also had lower relative hazards for 
coronary heart disease (adjusted subdistribution HR 0.73, 
95% CI 0.59 to 0.91) and stroke (0.63, 95% CI 0.45 to 0.89), 
considering death as a competing risk.
Conclusions MRFC may lower the increased risks 
for mortality and cardiovascular events in people 
with diabetes and CKD. Further research is needed to 
evaluate appropriateness of MRFC according to individual 
participants’ health status for improved management of 
cardiovascular risks in this population.
IntrODuCtIOn  
Diabetes and chronic kidney disease (CKD) 
are growing health problems worldwide, 
contributing to increased mortality.1 Diabetes 
and CKD also impose a substantial economic 
burden on society, with particularly high 
costs relating to cardiovascular complications 
and renal replacement therapy.2 3 The prev-
alence of CKD in patients with diabetes is 
between 4.2% and 17.9% (CKD stages 3–5) 
in European countries.4 The leading cause of 
death in people with type 2 diabetes or CKD 
is cardiovascular disease rather than renal 
complications.5 6 Prevention of cardiovas-
cular events is a key focus in the management 
of patients with these conditions.
Multifactorial interventions to reduce 
cardiovascular risks were shown to be effec-
tive at reducing mortality and cardiovascular 
events in patients with type 2 diabetes and 
persistent microalbuminuria in the Steno-2 
randomised trial.7 8 This study provided a 
high level of evidence, but included a rela-
tively small number of participants with 
diabetes who were managed in specialist 
centres. Recently, the implementation and 
strengths and limitations of this study
 ► This study included a large number of participants 
with type 2 diabetes and chronic kidney disease 
sampled from a representative general population 
with about 6 years of follow-up, which enabled to 
determine the associations of cardiovascular risk 
factors with mortality and cardiovascular events.
 ► Linked data for diagnostic data in hospitals and 
death registration with a primary care database en-
hanced the validity of the study to evaluate mortality 
and cardiovascular events.
 ► We could not conclude that associations represent-
ed causal relationships between multiple risk factor 
control and mortality and cardiovascular events in 
this non-randomised study.
 ► There is a possibility of confounding if healthier par-
ticipants were managed more successfully and this 
resulted in being categorised as those with greater 
number of risk factors controlled.
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effectiveness of this approach have been evaluated in 
patients with diabetes in clinical practice settings.9–11 
Epidemiological studies have demonstrated additional 
risks of CKD on mortality and cardiovascular diseases 
in people with diabetes,12 but treatment approaches in 
this population have not been well studied. No studies 
focused on multiple risk factor control (MRFC) in 
patients with both diabetes and CKD in a wide clinical 
practice setting. Generally, patients with kidney disease 
have been under-represented in cardiovascular clinical 
trials.13 This population may have an altered risk-benefit 
profile, and extrapolation of data based on patients with 
normal kidney function into patients with CKD may be 
unreliable.13 We aimed to conduct a pragmatic evaluation 
of the effectiveness of MRFC on mortality and cardiovas-
cular events in participants with type 2 diabetes and CKD 
in a population-based cohort study.
MEthODs
Data sources
This study employed a linked dataset derived from the 
UK Clinical Practice Research Datalink (CPRD), the 
UK National Health Service Hospital Episodes Statistics 
(HES) inpatient data and the UK Office for National 
Statistics (ONS) mortality data. The CPRD contains anony-
mised electronic health records from general practices 
across the UK.14 The CPRD collects data for diagnoses 
and clinical assessment, prescriptions and laboratory test 
results, such as Haemoglobin A1c (HbA1c) and serum 
creatinine. The HES inpatient data were comprised inpa-
tient records from all National Health Service hospitals 
in England. Information on the date of death and the 
causes of death was available in the ONS mortality data 
file. Multiple causes of death can be recorded in the 
mortality data. Diagnoses and clinical evaluation in the 
CPRD were coded with the Read codes, a hierarchical 
coding system used in primary care in the UK, whereas 
those in the HES and ONS were coded with the Interna-
tional Classification of Diseases, 10th Revision (ICD-10). 
Linked data are available for general practices in England 
only and participants were limited to those with linked 
data for the HES and ONS available.
study population
The scheme of the study cohort selection is presented 
in online supplementary figure S1. We initially sampled 
participants who were diagnosed with type 2 diabetes 
from the CPRD.15 Using the CPRD records, the date of 
the first valid serum creatinine value between 2006 and 
2010 recorded more than 1 year after the first diagnosis 
of diabetes were defined as the index date. A similar 
approach was taken by Adamsson Eryd et al16 to ensure 
that participants managed for diabetes had sufficient 
time available for recording of baseline values. To avoid 
misclassification of CKD status and stage, the index serum 
creatinine values were validated by confirmation of subse-
quent values within 30% of the index values. We restricted 
the sample to participants aged 40–79 years at the index 
date with at least 1 year of follow-up data available (ie, 
participants who died in the first year of follow-up were 
excluded). Estimated glomerular filtration rate (eGFR) 
was calculated from a serum creatinine value, age, gender 
and ethnicity, using the CKD Epidemiology Collaboration 
equation.17 Missing ethnicity was assumed as ‘non-black’ 
in the present study. Participants diagnosed with end-stage 
renal disease, those who had received renal replacement 
therapy, or those with index eGFR <15 mL/min/1.73 m2 
were excluded. We also excluded participants with missing 
data for smoking status, body mass index (BMI), HbA1c, 
blood pressure or total cholesterol, or those with extreme 
BMI (<18.5 or ≥45 kg/m2) at baseline. Since it has been 
reported that low values of cardiovascular risk factors were 
not always associated with better outcomes in observa-
tional studies,15 18 19 possibly due to reverse causation,20 21 
participants with low HbA1c (<42 mmol/mol or <6.0%), 
blood pressure (systolic <120 or diastolic <60 mm Hg) and 
total cholesterol (<3 mmol/L) were further excluded. 
Participants were categorised according to index eGFR 
into participants with CKD (<60 mL/min/1.73 m2) and 
those with non-CKD (≥60 mL/min/1.73 m2).
Multiple risk factor control
MRFC was defined in this study as consisting of four 
components: (1) HbA1c <53 mmol/mol (<7.0%), (2) 
blood pressure <140/90 mm Hg (systolic <140 and 
diastolic <90 mm Hg), (3) total cholesterol <5 mmol/L 
and (4) no smoking (non-smokers or ex-smokers). The 
means of HbA1c, blood pressure and total cholesterol 
records within 1 year before the index date were evalu-
ated. The number of the risk factors controlled from 
four criteria was treated as the exposure and included 
as a categorical variable in the main analyses, with those 
meeting no or one criterion as a reference category.
Outcomes
Main outcomes of interest in this study included all-cause 
and cardiovascular mortality, fatal and non-fatal coro-
nary heart disease (CHD) and stroke. The date of death 
and causes of death were determined using the ONS 
mortality data. Participants who died from cardiovascular 
causes were identified if people had any of the ICD-10 
codes I00–I99 as a cause of death. Similarly, participants 
who died from renal causes were identified by the ICD-10 
codes N17–N19. All of the CPRD, HES and ONS were 
used to ascertain fatal and non-fatal CHD and stroke. 
Read codes for CHD and stroke reported previously22 23 
were updated for the present study. The ICD-10 codes for 
CHD and stroke were I20–I25 and I60–I64, respectively.
Analysis
Baseline characteristics of the study cohort were 
described according to CKD status. Time-to-event anal-
yses were conducted to evaluate the associations of MRFC 
with mortality and cardiovascular events. To address the 
issue of reverse causation and to avoid misclassification 
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of the outcomes from those which had existed at base-
line, person-years for participants who experienced 
outcomes of interest in the first year of follow-up were 
excluded from analyses (online supplementary figure 
S1). Cox proportional hazards models were used to eval-
uate the association of MRFC with all-cause mortality. 
Proportional hazards assumption was assessed by visual 
inspection of log–log plots, and no apparent violation 
was found. Competing risks regression with subdistri-
bution hazard models were conducted for cardiovas-
cular mortality and cardiovascular events, considering 
competing risks for non-cardiovascular and all-cause 
death, respectively.24 Associations of MRFC with cardio-
vascular events were evaluated in participants without 
a known history of cardiovascular diseases at baseline 
(online supplementary figure S1). Participants were 
followed from the index date until the earliest of the 
events of interest, the last date of CPRD records or 31 
March 2015 for all-cause mortality evaluation. In the 
competing risks regression analyses for cardiovascular 
mortality and cardiovascular events, participants who 
experienced the corresponding competing events prior 
to the event of interest were censored.
Main analyses were conducted by CKD status, adjusting 
for a range of baseline covariates, including age (contin-
uous), gender (male or female), CKD stage (3a, 3b and 
4; for CKD cohort), BMI (18.5–24.9, 25.0–29.9, 30.0–
34.9, 35.0–39.9 and 40.0–44.9 kg/m2), deprivation level 
(quintile; 1, least deprived, to 5, most deprived), dura-
tion of diabetes (1.0–4.9, 5.0–9.9 and 10+ years), protein-
uria status, including microalbuminuria (yes, no and a 
missing category), a history of cardiovascular diseases, 
including CHD and stroke (for mortality evaluation), and 
prescribing during 6 months prior to the index date of 
antidiabetic drugs (none, insulin with and without other 
antidiabetic drugs, and non-insulin drugs only), antihy-
pertensive drugs (none, drugs acting on renin–angio-
tensin system with and without other antihypertensive 
drugs, and other classes of antihypertensive drugs only, 
including β-blockers, calcium channel blockers and 
thiazide diuretics), statins and antiplatelet drugs, and 
index year (2006–2010). In addition, the associations of 
CKD with the outcomes were evaluated according to the 
number of risk factors controlled, adjusting for the poten-
tial confounding factors.
In this paper, the results for participants with CKD 
were focused on, with the results for those with non-CKD 
shown for comparative purposes. The associations of each 
component of MRFC with the outcomes were also evalu-
ated to aid interpretation of the study results. All anal-
yses were performed using Stata V.14 (Stata Corp). The 
‘forestplot’ package in R was used to present the results.25
Patient and public involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in developing plans for design or implementation of the 
study. No patients were asked to advise on interpretation 
or writing up of results. Results will be disseminated to 
relevant patient communities through news media.
rEsults
Characteristics of the study population
Baseline characteristics of the study cohort are shown 
according to CKD status in table 1. Mean index eGFR 
was 49 mL/min/1.73 m2 for participants with CKD and 
81 mL/min/1.73 m2 for those with non-CKD. Participants 
with CKD were older (71 vs 62 years), included more 
women (52% vs 40%), had a longer duration of diabetes 
and were more likely to have a history of cardiovascular 
diseases (37% vs 22%). A higher frequency of protein-
uria was recorded in participants with CKD (18% vs 12% 
among participants with records of proteinuria status). 
HbA1c and total cholesterol were slightly lower in partic-
ipants with CKD. Although diastolic blood pressure was 
lower in participants with CKD, systolic blood pressure 
was higher despite more people under antihyperten-
sive medications. Participants with CKD were prescribed 
insulin, drugs on renin–angiotensin system, statins and 
antiplatelet drugs more frequently.
Implementation of MrFC
A number of risk factors controlled from four compo-
nents of MRFC are shown in table 2. More detailed results 
of which of the components were controlled are available 
in online supplementary table S1. Higher rates of control 
for HbA1c, total cholesterol and smoking status were 
observed in participants with CKD compared with those 
with non-CKD. However, blood pressure was less likely 
managed in participants with CKD (46% vs 51%). There 
were some differences in management status according 
to a history of cardiovascular diseases; in participants with 
CKD, higher rates of control of blood pressure (49% vs 
44%) and total cholesterol (83% vs 76%) in participants 
with a history of cardiovascular diseases compared with 
those without. Participants meeting three or four criteria 
accounted for 37% or 13% in participants with CKD.
Effectiveness of MrFC
Absolute risks for mortality and cardiovascular diseases 
and adjusted relative hazards of the number of risk 
factors controlled for the outcomes are shown in figure 1. 
Increasing numbers of risk factors controlled were associ-
ated with lower relative hazards for all outcomes studied 
relative to participants meeting no or one criterion. For 
participants with CKD meeting four MRFC criteria, the 
adjusted HR for all-cause mortality was 0.60 (95% CI 0.53 
to 0.69) and adjusted subdistribution HR for cardiovas-
cular mortality was 0.60 (95% CI 0.50 to 0.70). Participants 
meeting four criteria also had lower relative risks for CHD 
(adjusted subdistribution HR 0.73, 95% CI 0.59 to 0.91) 
and stroke (0.63, 95% CI 0.45 to 0.89) in participants with 
CKD. In participants with non-CKD, increasing numbers 
of risk factors controlled were also associated with lower 
risks for all-cause and cardiovascular mortality, CHD and 
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stroke. As shown in online supplementary figure S2, the 
strengths of associations of each component of MRFC 
with mortality and cardiovascular diseases were different; 
for example, the greatest associations of no smoking with 
all-cause and cardiovascular mortality were observed in 
participants with and without CKD.
Comparisons between CKD and non-CKD
Unadjusted absolute risks for mortality and cardiovas-
cular diseases were higher in participants with CKD by 
1.4-fold to 2.9-fold compared with those with non-CKD 
at the same MRFC category (figure 1). More participants 
Table 1 Baseline characteristics of the study cohort by 
CKD status
CKD
(n=11 431)
Non-CKD
(n=36 429) P values
Age (years) 
  Mean (SD) 71 (6) 62 (9) <0.001
Gender 
  Male 5481 (48) 22 006 (60) <0.001
  Female 5950 (52) 14 423 (40)
eGFR (mL/min/ 1.73 m2)
  Mean (SD) 49 (9) 81 (13) –
  15–29 558 (5) –
  30–44 2655 (23) –
  45–59 8218 (72) –
Smoking status 
  Non-smoker 5426 (47) 16 511 (45) <0.001
  Ex-smoker 4327 (38) 12 217 (34)
  Current smoker 1678 (15) 7701 (21)
BMI (kg/m2) 
  18.5–24.9 1459 (13) 4097 (11) <0.001
  25.0–29.9 4329 (38) 13 054 (36)
  30.0–34.9 3527 (31) 11 485 (32)
  35.0–39.9 1541 (13) 5454 (15)
  40.0–44.9 575 (5) 2339 (6)
Deprivation level 
(quintile) 
  1 (least deprived) 1508 (13) 4785 (13) 0.293
  2 2331 (20) 7300 (20)
  3 2374 (21) 7640 (21)
  4 2637 (23) 8172 (22)
  5 (most deprived) 2581 (23) 8532 (23)
Duration of diabetes 
(years) 
  1.0–4.9 5208 (46) 22 527 (62) <0.001
  5.0–9.9 2954 (26) 8356 (23)
  ≥10.0 3269 (29) 5546 (15)
Proteinuria 
  Yes 1714 (15) 3279 (9) <0.001
  No 7666 (67) 24 110 (66)
  Missing 2051 (18) 9040 (25)
History of coronary heart 
disease and/or stroke 
4215 (37) 7860 (22) <0.001
HbA1c (mmol/mol or %) 
  42–47 (6.0–6.4)* 1307 (11) 3513 (10) <0.001
  48–52 (6.5–6.9) 3041 (27) 8900 (24)
  53–57 (7.0–7.4) 2590 (23) 7781 (21)
  58–63 (7.5–7.9) 1709 (15) 5461 (15)
  64–68 (8.0–8.4) 1038 (9) 3567 (10)
  ≥69 (≥8.5) 1746 (15) 7207 (20)
Continued
CKD
(n=11 431)
Non-CKD
(n=36 429) P values
Systolic blood pressure (mm Hg) 
  120–129 1777 (16) 7203 (20) <0.001
  130–139 3508 (31) 12 121 (33)
  140–149 3387 (30) 10 242 (28)
  ≥150 2759 (24) 6863 (19)
Diastolic blood pressure (mm Hg) 
  60–79 7238 (63) 16 803 (46) <0.001
  80–89 3599 (31) 15 816 (43)
  ≥90 594 (5) 3810 (10)
Total cholesterol (mmol/L) 
  3.0–3.9 3782 (33) 10 960 (30) <0.001
  4.0–4.9 5220 (46) 16 387 (45)
  ≥5.0 2429 (21) 9082 (25)
Medication 
  Antidiabetic drugs <0.001
   Insulin (±non-insulin) 1805 (16) 3225 (9)
   Non-insulin only 7722 (68) 26 753 (73)
  Antihypertensive drugs <0.001
   Drugs on renin–
angiotensin system 
(±others)
8472 (74) 21 535 (59)
   Other 
antihypertensive 
drugs only
1610 (14) 4751 (13)
  Statins 9004 (79) 27 011 (74) <0.001
  Antiplatelet drugs 6440 (56) 16 375 (45) <0.001
Index years 
  2006 9091 (80) 24 192 (66) <0.001
  2007 1008 (9) 3741 (10)
  2008 545 (5) 2880 (8)
  2009 432 (4) 2677 (7)
  2010 355 (3) 2939 (8)
Frequencies (percentages) are shown otherwise specified.
*Participants with HbA1c <48 mmol/mol (<6.5%) were only 
included if they were prescribed antidiabetic drugs.
BMI, body mass index; CKD, chronic kidney disease; eGFR, 
estimated glomerular filtration rate.
Table 1 Continued 
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with CKD died from cardiovascular causes compared with 
those without (63% vs 54%, p<0.001). More participants 
with CKD died from renal causes (n=631 or 5% vs n=326 or 
0.9%, p<0.001), but the proportions were much smaller 
than cardiovascular causes of death. Relative hazards of 
CKD for the outcomes are shown in figure 2. After adjust-
ment with possible confounding factors, comorbid CKD 
remained to be associated with greater risks for all-cause 
mortality (adjusted HR 1.16 to 1.30) and cardiovascular 
mortality (adjusted subdistribution HR 1.25 to 1.41). In 
participants meeting two or more criteria, comorbid CKD 
was associated with a higher risk for CHD (1.18 to 1.25). 
The associations of comorbid CKD with stroke were 
observed in participants meeting four criteria only (1.64).
DIsCussIOn
In this population-based cohort study of participants with 
type 2 diabetes and CKD stages 3 or 4, MRFC was associ-
ated with lower relative risks for mortality and cardiovas-
cular diseases. We also confirmed that CKD was associated 
with increased risks for mortality and cardiovascular 
events. Higher absolute risks for mortality and cardiovas-
cular events and great relative risk reduction associated 
with MRFC suggest that the MRFC strategy may be one of 
the main approaches to potentially reducing the burden 
of diabetes and CKD.
This study evaluated the effectiveness of MRFC in patients 
with type 2 diabetes according to presence or absence of 
CKD in clinical practice. So far, the associations of MRFC 
with lower risks for mortality and cardiovascular events 
have been shown in people with diabetes, not focusing on 
CKD status. Participants with controlled three risk factors 
of HbA1c, blood pressure and low-density lipoprotein 
(LDL) cholesterol had 62% and 60% risk reduction for 
cardiovascular events and CHD, respectively, in patients 
with diabetes without known cardiovascular diseases.10 
The associations of uncontrolled HbA1c, blood pressure, 
LDL cholesterol and smoking with mortality and cardiovas-
cular events were individually evaluated in a large popula-
tion-based study with >850 000 participants with diabetes.11 
The study cohort included 35.5% of participants with CKD 
in those with cardiovascular diseases and 21.8% in those 
without, and CKD was included in the analyses for adjust-
ment. This study suggested that uncontrolled risk factors 
attributed to about 1 in 3 major cardiovascular events and 
fewer 1 in 10 deaths.
The strength of this study was the inclusion of a large 
size of >11 000 participants with diabetes and CKD with an 
observation of >62 000 person-years. In addition to the large 
sample size and long-term follow-up, representativeness 
from general population and data quality are also advan-
tages of the CPRD,14 which should remain even if linked 
data for the HES and ONS are only available for England 
practices. Instead, linked data for diagnoses in hospitals 
and death registration substantially enhanced the validity 
of the study to evaluate mortality and cardiovascular events.
There are also some limitations in this study. First, 
despite our focus on the number of MRFC, the impacts 
of each component of MRFC on mortality and cardio-
vascular events were different. Different cut-off points 
for HbA1c, blood pressure and total cholesterol may 
bring different results. Next, we could not conclude 
that associations represented causal relationships 
between MRFC and mortality and cardiovascular events 
in this non-randomised study. There is a possibility of 
confounding if healthier participants were managed 
more successfully and this resulted in being categorised 
as those with greater number of risk factors controlled. 
Table 2 Risk factors controlled according to CKD and a history of CVD
CKD Non-CKD
Total
(n=11 431)
No CVD
(n=7216)
CVD
(n=4215)
Total
(n=36 429)
No CVD
(n=28 569)
CVD
(n=7860)
Individual risk factor controlled
  HbA1c <53 mmol/mol (<7.0%) 4348 (38) 2767 (38) 1581 (38) 12 413 (34) 9603 (34) 2810 (36)
  Blood pressure <140 and 
<90 mm Hg
5224 (46) 3147 (44) 2077 (49) 18 655 (51) 14 438 (51) 4217 (54)
  Total cholesterol <5 mmol/L 9002 (79) 5512 (76) 3490 (83) 27 347 (75) 20 826 (73) 6521 (83)
  No smoking 9753 (85) 6193 (86) 3560 (84) 28 728 (79) 22 565 (79) 6163 (78)
No of risk factors controlled
  0 138 (1) 87 (1) 51 (1) 806 (2) 678 (2) 128 (2)
  1 1427 (12) 971 (13) 456 (11) 5372 (15) 4421 (15) 951 (12)
  2 4162 (36) 2693 (37) 1469 (35) 13 288 (36) 10 602 (37) 2686 (34)
  3 4240 (37) 2598 (36) 1642 (39) 12 657 (35) 9665 (34) 2992 (38)
  4 1464 (13) 867 (12) 597 (14) 4306 (12) 3203 (11) 1103 (14)
Frequencies (percentages) are shown.
CKD, chronic kidney disease; CVD, (a history of) cardiovascular diseases.
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Figure 1 Relative hazards of the number of risk factors controlled for mortality and cardiovascular events in (A) participants 
with chronic kidney disease (CKD) and (B) participants with non-CKD. HRs for all-cause mortality and subdistribution HRs 
(SHRs) for cardiovascular mortality, coronary heart disease (CHD) and stroke were adjusted for age, gender, CKD stage (for CKD 
cohort), body mass index, deprivation level, duration of diabetes, proteinuria status, a history of cardiovascular diseases (for 
mortality evaluation), prescribing of antidiabetic, antihypertensive, statins and antiplatelet drugs, and index year.
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For example, stringent management of HbA1c might 
not be targeted for vulnerable participants due to 
concerns for greater risk of hypoglycaemia, a form of 
confounding by contraindication. We cannot exclude 
the possibility of residual confounding, despite adjust-
ment with a range of covariates in the analyses, including 
physical activity and alcohol intake.26 27 Then, measure-
ment and assay methods for HbA1c, blood pressure, 
cholesterol and serum creatinine might not have been 
standardised among general practices or laboratories. 
As well as missing data on ethnicity and fluctuations in 
serum creatinine values, these methodological limita-
tions might influence the determination of CKD status 
or staging. Although proteinuria has been known as a 
risk factor for mortality and cardiovascular diseases,28 29 
we could not determine proteinuria status completely as 
reported previously.30 31 Incomplete records on protein-
uria may introduce a bias for proteinuria status and 
possibly influence the study results. Finally, although we 
used one of the largest primary care electronic health 
Figure 2 Relative hazards of presence of chronic kidney disease (CKD) for mortality and cardiovascular events compared with 
non-CKD as reference. HRs for all-cause mortality and subdistribution HRs (SHRs) for cardiovascular mortality, coronary heart 
disease (CHD) and stroke were adjusted for age, gender, body mass index, deprivation level, duration of diabetes, proteinuria 
status, a history of cardiovascular diseases (for mortality evaluation), prescribing of antidiabetic, antihypertensive, statins and 
antiplatelet drugs, and index year.
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records database, it seemed to be insufficient to sepa-
rately evaluate MRFC for participants with different 
stages of CKD. Further research is needed to focus 
on patients with more advanced CKD who may have 
altered risk-benefit profile compared with patients with 
less impaired renal function.
In summary, based on the population-based cohort study 
of routine clinical practices, MRFC may lower the increased 
risks for mortality and cardiovascular events in people with 
diabetes and CKD. Further research is needed to evaluate 
appropriateness of MRFC according to individual partici-
pants’ health status for improved management of cardiovas-
cular risks in this population.
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